JP7634001B2 - ４－１ｂｂに結合する抗体およびその用途 - Google Patents

４－１ｂｂに結合する抗体およびその用途 Download PDF

Info

Publication number
JP7634001B2
JP7634001B2 JP2022522002A JP2022522002A JP7634001B2 JP 7634001 B2 JP7634001 B2 JP 7634001B2 JP 2022522002 A JP2022522002 A JP 2022522002A JP 2022522002 A JP2022522002 A JP 2022522002A JP 7634001 B2 JP7634001 B2 JP 7634001B2
Authority
JP
Japan
Prior art keywords
antibody
chain variable
amino acid
variable region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522002A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021068841A5 (https=
JP2022553922A5 (https=
JP2022553922A (ja
Inventor
カン シアオチアン
シアオ ホアン
チエンミン スン
Original Assignee
ナンチン リーズ バイオラブス カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナンチン リーズ バイオラブス カンパニー，リミティド filed Critical ナンチン リーズ バイオラブス カンパニー，リミティド
Publication of JP2022553922A publication Critical patent/JP2022553922A/ja
Publication of JPWO2021068841A5 publication Critical patent/JPWO2021068841A5/ja
Publication of JP2022553922A5 publication Critical patent/JP2022553922A5/ja
Priority to JP2025019263A priority Critical patent/JP2025069432A/ja
Application granted granted Critical
Publication of JP7634001B2 publication Critical patent/JP7634001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022522002A 2019-10-11 2020-09-30 ４－１ｂｂに結合する抗体およびその用途 Active JP7634001B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019263A JP2025069432A (ja) 2019-10-11 2025-02-07 ４－１ｂｂに結合する抗体およびその用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913744P 2019-10-11 2019-10-11
US62/913,744 2019-10-11
PCT/CN2020/119388 WO2021068841A1 (en) 2019-10-11 2020-09-30 Antibodies binding 4-1bb and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019263A Division JP2025069432A (ja) 2019-10-11 2025-02-07 ４－１ｂｂに結合する抗体およびその用途

Publications (4)

Publication Number Publication Date
JP2022553922A JP2022553922A (ja) 2022-12-27
JPWO2021068841A5 JPWO2021068841A5 (https=) 2023-05-10
JP2022553922A5 JP2022553922A5 (https=) 2023-05-10
JP7634001B2 true JP7634001B2 (ja) 2025-02-20

Family

ID=75382666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522002A Active JP7634001B2 (ja) 2019-10-11 2020-09-30 ４－１ｂｂに結合する抗体およびその用途
JP2025019263A Pending JP2025069432A (ja) 2019-10-11 2025-02-07 ４－１ｂｂに結合する抗体およびその用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019263A Pending JP2025069432A (ja) 2019-10-11 2025-02-07 ４－１ｂｂに結合する抗体およびその用途

Country Status (5)

Country Link
US (2) US11466086B2 (https=)
EP (1) EP4041772A4 (https=)
JP (2) JP7634001B2 (https=)
CN (2) CN117586400A (https=)
WO (1) WO2021068841A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025069432A (ja) * 2019-10-11 2025-04-30 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118684772A (zh) * 2021-09-09 2024-09-24 广东东阳光药业股份有限公司 抗4-1bb的激动型抗体及其应用
WO2023168547A1 (en) * 2022-03-07 2023-09-14 Adagene Pte. Ltd. Anti-cd137 antibodies and methods of making and using the same
EP4584300A1 (en) * 2022-09-06 2025-07-16 TJ Biopharma (Shanghai) Co., Ltd. Multispecific constructs and uses thereof
JP2026508244A (ja) 2023-02-22 2026-03-10 ナンジング リーズ バイオラブズ シーオー．， エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
WO2025067330A1 (zh) * 2023-09-27 2025-04-03 南京维立志博生物科技股份有限公司 用于治疗肿瘤的抗pd-l1和抗4-1bb双特异性抗体
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2026061538A1 (zh) * 2024-09-23 2026-03-26 南京维立志博生物科技股份有限公司 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
JP2018520650A (ja) 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
JP2019504831A (ja) 2016-01-11 2019-02-21 インヒブルクス インコーポレイテッド 多価かつ多重特異性の４１ｂｂ結合融合タンパク質

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
TW201632559A (zh) 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
IL268836B2 (en) * 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN111194323B (zh) 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
TWI701259B (zh) 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
CA3100119A1 (en) 2018-07-31 2020-02-06 Pieris Pharmaceuticals Gmbh Fusion protein specific for cd137 and pd-l1
CN109021107B (zh) 2018-09-05 2020-08-28 江苏诺迈博生物医药科技有限公司 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒
CN119798453A (zh) 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
CN113286825B (zh) 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
US11466086B2 (en) * 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520650A (ja) 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
JP2019504831A (ja) 2016-01-11 2019-02-21 インヒブルクス インコーポレイテッド 多価かつ多重特異性の４１ｂｂ結合融合タンパク質
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018056821A1 (en) 2016-09-23 2018-03-29 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025069432A (ja) * 2019-10-11 2025-04-30 ナンチン リーズ バイオラブス カンパニー，リミティド ４－１ｂｂに結合する抗体およびその用途

Also Published As

Publication number Publication date
US20230192862A1 (en) 2023-06-22
JP2025069432A (ja) 2025-04-30
CN117586400A (zh) 2024-02-23
CN114555638B (zh) 2023-08-22
WO2021068841A1 (en) 2021-04-15
CN114555638A (zh) 2022-05-27
US20210107982A1 (en) 2021-04-15
EP4041772A4 (en) 2024-04-24
US11466086B2 (en) 2022-10-11
EP4041772A1 (en) 2022-08-17
JP2022553922A (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
JP7634001B2 (ja) ４－１ｂｂに結合する抗体およびその用途
US10442866B1 (en) Antibodies binding OX40 and uses thereof
US10577424B1 (en) Antibodies binding VISTA and uses thereof
JP7827951B2 (ja) 抗体結合Ｓｉｇｌｅｃ１５及びその使用
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
JP7535503B2 (ja) Ｐｄ－１に結合する抗体及びその使用
US20220396617A1 (en) Antibodies binding tigit and uses thereof
JP7600487B2 (ja) Ｐｄ－ｌ１と結合する抗体及びその使用
JP7571348B2 (ja) Ｐｄ－１結合抗体及びその用途
JP7440724B2 (ja) Ｃｔｌａ４に結合する抗体及びその使用
HK40066858A (zh) 结合4-1bb的抗体及其用途
HK40066858B (zh) 结合4-1bb的抗体及其用途
HK40045182A (en) Antibody binding pd-1 and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250207

R150 Certificate of patent or registration of utility model

Ref document number: 7634001

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150